Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica, a leader in cell and gene therapy manufacturing, announced the appointment of Heather Preston as Non-Executive Director to Aligos Therapeutics. The company, recognized for its expertise in viral vectors and innovative bioprocessing technologies, plays a crucial role in partnering with major biotech firms. With over 25 years’ experience, Oxford Biomedica continues to impact the delivery of life-changing therapies worldwide.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
